Watchlist Price Alert

Insulet Corporation (PODD)

NASDAQ: PODD · Real-Time Price · USD

257.01

6.76 (2.70%)

At close: May 02, 2025, 3:59 PM

256.90

-0.04%

Pre-market: May 05, 2025, 04:27 AM EDT

2.70% (1D)

Bid	250.5
Market Cap	18.05B
Revenue (ttm)	1.9B
Net Income (ttm)	418.3M
EPS (ttm)	5.78
PE Ratio (ttm)	44.47
Forward PE	47.51
Analyst	Buy

Ask	260.05
Volume	683,385
Avg. Volume (20D)	806,620
Open	255.49
Previous Close	250.25
Day's Range	254.72 - 259.25
52-Week Range	160.19 - 289.46
Beta	1.30

About PODD

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly i...

[Read more]

Industry Medical - Devices

Sector Healthcare

IPO Date May 15, 2007

Employees 3,900

Stock Exchange NASDAQ

Ticker Symbol PODD

Website https://www.insulet.com

Full Company Profile

Analyst Forecast

According to 17 analyst ratings, the average rating for PODD stock is "Buy." The 12-month stock price forecast is $313.5, which is an increase of 21.98% from the latest price.

Stock Forecasts

Next Earnings Release

Insulet Corporation is scheduled to release its earnings on May 8, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

6 days ago

-3.18%

Insulet shares are trading lower after Wolfe Resea... Unlock content with Pro Subscription

4 months ago

+3.68%

Insulet shares are trading higher after TD Cowen raised its price target on the stock from $264 to $324.

News

6 days ago · investopedia.com

Insulet Names New CEO, Expects to Top Revenue Projections

Insulet (PODD) shares edged lower Monday as the maker of an insulin delivery device for diabetes patients announced a shakeup in its leadership.

1 week ago · businesswire.com

Insulet Appoints Ashley McEvoy President and CEO

ACTON, Mass.--(BUSINESS WIRE)--Insulet Appoints Ashley McEvoy President and CEO.

2 weeks ago · zacks.com

4 Medical Product Stocks to Buy From a Challenging Industry

The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR are likely to gain from ...

3 weeks ago · zacks.com

Strength Seen in Insulet (PODD): Can Its 7.2% Jump Turn into More Strength?

Insulet (PODD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

3 weeks ago · zacks.com

5 High-Flying Large-Cap Stocks to Buy Amid Tariff-Led Market Rout

Despite Extreme volatility, these five stocks have provided more than 4% returns past month. These are: SFM, UNH, SRAD, GME, PODD.

3 weeks ago · zacks.com

PODD Stock Benefits From the Launch of Omnipod 5 in Canada

Insulet announces the commercial launch of Omnipod 5 AID system in Canada, with Dexcom G6 and G7 CGM sensor compatibility.

1 month ago · businesswire.com

Insulet to Announce First Quarter 2025 Financial Results on May 8, 2025

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced p...

1 month ago · zacks.com

Insulet Gains 62.9% in a Year: What's Driving the Stock?

PODD's shares rise on the back of its innovative Omnipod 5 system and impressive market expansion. However, the unfavorable macroeconomic scenario is concerning.